Wesley T Lindsey1, David Stewart, Darrell Childress. 1. Department of Pharmacy Practice, Drug Information and Learning Resource Center, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA. wtl0001@auburn.edu
Abstract
OBJECTIVE: The aim was to summarize the clinical literature on interactions between common illicit drugs and prescription therapies. METHODS: Medline, Iowa Drug Information Service, International Pharmaceutical Abstracts, EBSCO Academic Search Premier, and Google Scholar were searched from date of origin of database to March 2011. Search terms were cocaine, marijuana, cannabis, methamphetamine, amphetamine, ecstasy, N-methyl-3,4-methylenedioxymethamphetamine, methylenedioxymethamphetamine, heroin, gamma-hydroxybutyrate, sodium oxybate, and combined with interactions, drug interactions, and drug-drug interactions. This review focuses on established clinical evidence. All applicable full-text English language articles and abstracts found were evaluated and included in the review as appropriate. RESULTS: The interactions of illicit drugs with prescription therapies have the ability to potentiate or attenuate the effects of both the illicit agent and/or the prescription therapeutic agent, which can lead to toxic effects or a reduction in the prescription agent's therapeutic activity. Most texts and databases focus on theoretical or probable interactions due to the kinetic properties of the drugs and do not fully explore the pharmacodynamic and clinical implications of these interactions. Clinical trials with coadministration of illicit drugs and prescription drugs are discussed along with case reports that demonstrate a potential interaction between agents. The illicit drugs discussed are cocaine, marijuana, amphetamines, methylenedioxymethamphetamine, heroin, and sodium oxybate. CONCLUSION: Although the use of illicit drugs is widespread, there are little experimental or clinical data regarding the effects of these agents on common prescription therapies. SCIENTIFIC SIGNIFICANCE: Potential drug interactions between illicit drugs and prescription drugs are described and evaluated on the Drug Interaction Probability Scale by Horn and Hansten.
OBJECTIVE: The aim was to summarize the clinical literature on interactions between common illicit drugs and prescription therapies. METHODS: Medline, Iowa Drug Information Service, International Pharmaceutical Abstracts, EBSCO Academic Search Premier, and Google Scholar were searched from date of origin of database to March 2011. Search terms were cocaine, marijuana, cannabis, methamphetamine, amphetamine, ecstasy, N-methyl-3,4-methylenedioxymethamphetamine, methylenedioxymethamphetamine, heroin, gamma-hydroxybutyrate, sodium oxybate, and combined with interactions, drug interactions, and drug-drug interactions. This review focuses on established clinical evidence. All applicable full-text English language articles and abstracts found were evaluated and included in the review as appropriate. RESULTS: The interactions of illicit drugs with prescription therapies have the ability to potentiate or attenuate the effects of both the illicit agent and/or the prescription therapeutic agent, which can lead to toxic effects or a reduction in the prescription agent's therapeutic activity. Most texts and databases focus on theoretical or probable interactions due to the kinetic properties of the drugs and do not fully explore the pharmacodynamic and clinical implications of these interactions. Clinical trials with coadministration of illicit drugs and prescription drugs are discussed along with case reports that demonstrate a potential interaction between agents. The illicit drugs discussed are cocaine, marijuana, amphetamines, methylenedioxymethamphetamine, heroin, and sodium oxybate. CONCLUSION: Although the use of illicit drugs is widespread, there are little experimental or clinical data regarding the effects of these agents on common prescription therapies. SCIENTIFIC SIGNIFICANCE: Potential drug interactions between illicit drugs and prescription drugs are described and evaluated on the Drug Interaction Probability Scale by Horn and Hansten.
Authors: Jennifer McNeely; Charles M Cleland; Shiela M Strauss; Joseph J Palamar; John Rotrosen; Richard Saitz Journal: J Gen Intern Med Date: 2015-05-19 Impact factor: 5.128
Authors: Jennifer McNeely; Shiela M Strauss; Richard Saitz; Charles M Cleland; Joseph J Palamar; John Rotrosen; Marc N Gourevitch Journal: Am J Med Date: 2015-03-10 Impact factor: 4.965
Authors: Allison Derise; Carey Ford; Nazar Hafiz; Sudha Pandit; Aditya Vyas; Samuel Igbinedion; James Morris; Paul Jordan; Qiang Cai; Jonathan Steven Alexander Journal: Pathophysiology Date: 2022-05-28
Authors: Amy C Justice; Matthew B Goetz; Cameron N Stewart; Brenna C Hogan; Elizabeth Humes; Paula M Luz; Jessica L Castilho; Denis Nash; Ellen Brazier; Beverly Musick; Constantin Yiannoutsos; Karen Malateste; Antoine Jaquet; Morna Cornell; Tinei Shamu; Reena Rajasuriar; Awachana Jiamsakul; Keri N Althoff Journal: Lancet HIV Date: 2022-02-23 Impact factor: 16.070
Authors: Pritika C Kumar; Charles M Cleland; Marc N Gourevitch; John Rotrosen; Shiela Strauss; Linnea Russell; Jennifer McNeely Journal: Drug Alcohol Depend Date: 2016-06-22 Impact factor: 4.492
Authors: Jennifer McNeely; Li-Tzy Wu; Geetha Subramaniam; Gaurav Sharma; Lauretta A Cathers; Dace Svikis; Luke Sleiter; Linnea Russell; Courtney Nordeck; Anjalee Sharma; Kevin E O'Grady; Leah B Bouk; Carol Cushing; Jacqueline King; Aimee Wahle; Robert P Schwartz Journal: Ann Intern Med Date: 2016-09-06 Impact factor: 25.391